Cargando…

Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease

Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and contin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fröhlich, Holger, Bontridder, Noémi, Petrovska-Delacréta, Dijana, Glaab, Enrico, Kluge, Felix, Yacoubi, Mounim El, Marín Valero, Mayca, Corvol, Jean-Christophe, Eskofier, Bjoern, Van Gyseghem, Jean-Marc, Lehericy, Stepháne, Winkler, Jürgen, Klucken, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918525/
https://www.ncbi.nlm.nih.gov/pubmed/35295840
http://dx.doi.org/10.3389/fneur.2022.788427
_version_ 1784668746576560128
author Fröhlich, Holger
Bontridder, Noémi
Petrovska-Delacréta, Dijana
Glaab, Enrico
Kluge, Felix
Yacoubi, Mounim El
Marín Valero, Mayca
Corvol, Jean-Christophe
Eskofier, Bjoern
Van Gyseghem, Jean-Marc
Lehericy, Stepháne
Winkler, Jürgen
Klucken, Jochen
author_facet Fröhlich, Holger
Bontridder, Noémi
Petrovska-Delacréta, Dijana
Glaab, Enrico
Kluge, Felix
Yacoubi, Mounim El
Marín Valero, Mayca
Corvol, Jean-Christophe
Eskofier, Bjoern
Van Gyseghem, Jean-Marc
Lehericy, Stepháne
Winkler, Jürgen
Klucken, Jochen
author_sort Fröhlich, Holger
collection PubMed
description Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions.
format Online
Article
Text
id pubmed-8918525
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89185252022-03-15 Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease Fröhlich, Holger Bontridder, Noémi Petrovska-Delacréta, Dijana Glaab, Enrico Kluge, Felix Yacoubi, Mounim El Marín Valero, Mayca Corvol, Jean-Christophe Eskofier, Bjoern Van Gyseghem, Jean-Marc Lehericy, Stepháne Winkler, Jürgen Klucken, Jochen Front Neurol Neurology Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918525/ /pubmed/35295840 http://dx.doi.org/10.3389/fneur.2022.788427 Text en Copyright © 2022 Fröhlich, Bontridder, Petrovska-Delacréta, Glaab, Kluge, Yacoubi, Marín Valero, Corvol, Eskofier, Van Gyseghem, Lehericy, Winkler and Klucken. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Fröhlich, Holger
Bontridder, Noémi
Petrovska-Delacréta, Dijana
Glaab, Enrico
Kluge, Felix
Yacoubi, Mounim El
Marín Valero, Mayca
Corvol, Jean-Christophe
Eskofier, Bjoern
Van Gyseghem, Jean-Marc
Lehericy, Stepháne
Winkler, Jürgen
Klucken, Jochen
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title_full Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title_fullStr Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title_full_unstemmed Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title_short Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
title_sort leveraging the potential of digital technology for better individualized treatment of parkinson's disease
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918525/
https://www.ncbi.nlm.nih.gov/pubmed/35295840
http://dx.doi.org/10.3389/fneur.2022.788427
work_keys_str_mv AT frohlichholger leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT bontriddernoemi leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT petrovskadelacretadijana leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT glaabenrico leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT klugefelix leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT yacoubimounimel leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT marinvaleromayca leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT corvoljeanchristophe leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT eskofierbjoern leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT vangyseghemjeanmarc leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT lehericystephane leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT winklerjurgen leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease
AT kluckenjochen leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease